English
|
Español
English
|
Español
Insurance
Marketing
Pharmaceuticals
Technology/Innovation
Regulatory
Community
The Oklahoma Proton Center LLC
+
Pharmaceuticals
Patient Daily
| Jun 10, 2025
Radiation oncologist on 340B program: ‘It is used as a consolidation tool by large institutions to kill competition in the market’
Trending
+
Pharmaceuticals
Patient Daily
| Aug 4, 2026
Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+
Pharmaceuticals
Patient Daily
| Aug 6, 2026
FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+
Regulatory
M. R. Armstrong
| Aug 4, 2026
Public Policy Solutions on 340B: 'The program has enriched big hospital execs'
+
Pharmaceuticals
Patient Daily
| Aug 5, 2026
Bristol Myers Squibb and AstraZeneca reportedly in merger talks amid industry changes
